DD298788A5 - Neue insulinverbindungen - Google Patents

Neue insulinverbindungen Download PDF

Info

Publication number: DD298788A5
Authority: DD; German Democratic Republic
Prior art keywords: insulin; arg; thr; leu; ser
Prior art date: 1989-03-20

Application number

DD90338860A

Other languages

German (de)

English (en)

Inventor

Per Balschmidt

Finn B Hansen

Original Assignee

��`��@�a�k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-20

Filing date

1990-03-19

Publication date

1992-03-12

1990-03-19 Application filed by ��`��@�a�k�� filed Critical ��`��@�a�k��

1992-03-12 Publication of DD298788A5 publication Critical patent/DD298788A5/de

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 181
102000004877 Insulin Human genes 0.000 title claims abstract description 81
108090001061 Insulin Proteins 0.000 title claims abstract description 81
229940125396 insulin Drugs 0.000 title claims abstract description 76
238000002360 preparation method Methods 0.000 claims description 62
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 35
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 35
238000000034 method Methods 0.000 claims description 27
239000002243 precursor Substances 0.000 claims description 27
239000000872 buffer Substances 0.000 claims description 14
-1 Insulin compound Chemical class 0.000 claims description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
125000000539 amino acid group Chemical group 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
108010059378 Endopeptidases Proteins 0.000 claims description 4
102000005593 Endopeptidases Human genes 0.000 claims description 4
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
230000007935 neutral effect Effects 0.000 claims description 3
239000012736 aqueous medium Substances 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
210000002966 serum Anatomy 0.000 claims description 2
230000009471 action Effects 0.000 abstract description 10
150000001413 amino acids Chemical group 0.000 abstract description 9
230000003111 delayed effect Effects 0.000 abstract description 8
239000004026 insulin derivative Substances 0.000 abstract description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 30
239000000243 solution Substances 0.000 description 24
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
150000001408 amides Chemical class 0.000 description 20
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
238000002347 injection Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
239000012634 fragment Substances 0.000 description 15
238000009396 hybridization Methods 0.000 description 15
239000011780 sodium chloride Substances 0.000 description 15
239000013613 expression plasmid Substances 0.000 description 14
240000004808 Saccharomyces cerevisiae Species 0.000 description 13
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
108020004414 DNA Proteins 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
239000000047 product Substances 0.000 description 12
230000000694 effects Effects 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
239000000203 mixture Substances 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000013612 plasmid Substances 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
239000000725 suspension Substances 0.000 description 9
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
108090000631 Trypsin Proteins 0.000 description 8
102000004142 Trypsin Human genes 0.000 description 8
229940024606 amino acid Drugs 0.000 description 8
239000004202 carbamide Substances 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
239000003999 initiator Substances 0.000 description 8
230000007774 longterm Effects 0.000 description 8
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 8
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
239000012588 trypsin Substances 0.000 description 8
108020004705 Codon Proteins 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
238000010521 absorption reaction Methods 0.000 description 7
238000010276 construction Methods 0.000 description 7
238000001914 filtration Methods 0.000 description 7
239000008103 glucose Substances 0.000 description 7
239000013598 vector Substances 0.000 description 7
229920001817 Agar Polymers 0.000 description 6
241000700159 Rattus Species 0.000 description 6
239000008272 agar Substances 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
239000000499 gel Substances 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
229920005654 Sephadex Polymers 0.000 description 5
239000012507 Sephadex™ Substances 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
239000007858 starting material Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
230000009466 transformation Effects 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
108010076181 Proinsulin Proteins 0.000 description 3
239000012614 Q-Sepharose Substances 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
238000004987 plasma desorption mass spectroscopy Methods 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
230000000979 retarding effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
108010092217 Long-Acting Insulin Proteins 0.000 description 2
102000016261 Long-Acting Insulin Human genes 0.000 description 2
229940100066 Long-acting insulin Drugs 0.000 description 2
101100270435 Mus musculus Arhgef12 gene Proteins 0.000 description 2
108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 2
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
108010005991 Pork Regular Insulin Proteins 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000006240 deamidation Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
PLFFHJWXOGYWPR-HEDMGYOXSA-N (4r)-4-[(3r,3as,5ar,5br,7as,11as,11br,13ar,13bs)-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-3-yl]pentan-1-ol Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1[C@@H](CCCO)C PLFFHJWXOGYWPR-HEDMGYOXSA-N 0.000 description 1
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
241000590020 Achromobacter Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
RGQCNKIDEQJEBT-CQDKDKBSSA-N Ala-Leu-Tyr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RGQCNKIDEQJEBT-CQDKDKBSSA-N 0.000 description 1
IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
101001011745 Canis lupus familiaris Insulin Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
102000005561 Human Isophane Insulin Human genes 0.000 description 1
108010084048 Human Isophane Insulin Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 1
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
241000863031 Lysobacter Species 0.000 description 1
108010053229 Lysyl endopeptidase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
108010016616 cysteinylglycine Proteins 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
108010081551 glycylphenylalanine Proteins 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940127560 insulin pen Drugs 0.000 description 1
HHMSPIAOYISBOU-IYQBICMXSA-N insulin rabbit Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 HHMSPIAOYISBOU-IYQBICMXSA-N 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
KIALCSMRIHRFPL-UHFFFAOYSA-N n-(2,5-diphenylpyrazol-3-yl)-4-nitrobenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NC1=CC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 KIALCSMRIHRFPL-UHFFFAOYSA-N 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
108010066381 preproinsulin Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940070353 protamines Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
238000007039 two-step reaction Methods 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
239000004246 zinc acetate Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DD90338860A 1989-03-20 1990-03-19 Neue insulinverbindungen DD298788A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK134189A DK134189D0 (da)	1989-03-20	1989-03-20	Insulinforbindelser

Publications (1)

Publication Number	Publication Date
DD298788A5 true DD298788A5 (de)	1992-03-12

Family

ID=8103787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90338860A DD298788A5 (de)	1989-03-20	1990-03-19	Neue insulinverbindungen

Country Status (23)

Country	Link
US (1)	US5430016A (pt)
EP (1)	EP0463072B1 (pt)
JP (1)	JPH04503808A (pt)
KR (1)	KR920701250A (pt)
CN (1)	CN1045793A (pt)
AT (1)	ATE116661T1 (pt)
AU (1)	AU637365B2 (pt)
CA (1)	CA2049961A1 (pt)
DD (1)	DD298788A5 (pt)
DE (1)	DE69015811T2 (pt)
DK (2)	DK134189D0 (pt)
ES (1)	ES2068384T3 (pt)
FI (1)	FI914419A0 (pt)
GR (1)	GR1002545B (pt)
HU (1)	HUT58349A (pt)
IE (1)	IE66564B1 (pt)
IL (1)	IL93792A0 (pt)
NO (1)	NO300640B1 (pt)
NZ (1)	NZ232953A (pt)
PT (1)	PT93502B (pt)
WO (1)	WO1990011299A1 (pt)
YU (1)	YU53290A (pt)
ZA (1)	ZA902086B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
DE3844211A1 (de) *	1988-12-29	1990-07-05	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
TW224471B (pt) *	1991-11-26	1994-06-01	Lilly Co Eli
US5948751A (en) *	1996-06-20	1999-09-07	Novo Nordisk A/S	X14-mannitol
HUP0004169A3 (en)	1997-10-24	2001-06-28	Lilly Co Eli	Insoluble insulin compositions and process for production thereof
CO4970787A1 (es) *	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US7378390B2 (en) *	1999-12-29	2008-05-27	Novo Nordisk A/S	Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
AU2002346490A1 (en) *	2001-12-20	2003-07-09	Eli Lilly And Company	Insulin molecule having protracted time action
WO2004096854A2 (en) *	2003-04-29	2004-11-11	Eli Lilly And Company	Insulin analogs having protracted time action
WO2009081262A1 (en) *	2007-12-18	2009-07-02	Insuline Medical Ltd.	Drug delivery device with sensor for closed-loop operation
EP2131723B1 (en) *	2007-03-19	2013-07-24	Insuline Medical Ltd.	Device for substance measurement
EP2131900B1 (en) *	2007-03-19	2018-05-30	Insuline Medical Ltd.	Drug delivery device
US9220837B2 (en)	2007-03-19	2015-12-29	Insuline Medical Ltd.	Method and device for drug delivery
US8622991B2 (en)	2007-03-19	2014-01-07	Insuline Medical Ltd.	Method and device for drug delivery
RU2524423C2 (ru)	2008-01-09	2014-07-27	Санофи-Авентис Дойчланд Гмбх	Новые производные инсулина с чрезвычайно замедленным профилем время/действие
KR20100111683A (ko) *	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
RU2532893C2 (ru)	2008-11-07	2014-11-10	Инсьюлин Медикал Лтд.	Устройство и способ доставки лекарственных средств
PH12011502708B1 (en)	2009-07-06	2017-11-10	Sanofi Aventis Deutschland	Insulin preparations containing methionine
JP5832439B2 (ja)	2009-11-13	2015-12-16	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
CN103179978A (zh)	2010-08-30	2013-06-26	赛诺菲-安万特德国有限公司	Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja)	2011-08-29	2018-08-01	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2992008B1 (en)	2013-05-02	2019-04-10	GlaxoSmithKline Intellectual Property Development Limited	Therapeutic peptides
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
CN106323840A (zh) *	2016-09-13	2017-01-11	西南石油大学	一种页岩孔隙度测量方法
CN109735589B (zh) *	2019-01-02	2020-07-10	珠海冀百康生物科技有限公司	一种胰岛素DesB30的制备方法
CN113773398B (zh) *	2020-06-10	2023-05-23	宁波鲲鹏生物科技有限公司	一种德谷胰岛素衍生物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55138393A (en) *	1979-04-13	1980-10-29	Shionogi & Co Ltd	Semisynthesis of insulin
DK147437A (en) *	1980-02-11	1900-01-01		Process for preparing human insulin or threonine B30 esters of human insulin, or a salt or complex thereof
IE50892B1 (en) *	1980-02-11	1986-08-06	Novo Industri As	Process for preparing insulin esters
DE3326473A1 (de) *	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) *	1983-07-22	1985-02-14	Hoechst Ag, 6230 Frankfurt	Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) *	1983-07-29	1985-02-07	Hoechst Ag, 6230 Frankfurt	Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK58285D0 (da) *	1984-05-30	1985-02-08	Novo Industri As	Peptider samt fremstilling og anvendelse deraf
DK113585D0 (da) *	1985-03-12	1985-03-12	Novo Industri As	Nye peptider
US4946828A (en) *	1985-03-12	1990-08-07	Novo Nordisk A/S	Novel insulin peptides
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
DK347086D0 (da) *	1986-07-21	1986-07-21	Novo Industri As	Novel peptides
DK119785D0 (da) *	1985-03-15	1985-03-15	Nordisk Gentofte	Insulinpraeparat
DK129385A (da) *	1985-03-22	1986-09-23	Novo Industri As	Peptider og fremstilling deraf
DK437786D0 (da) *	1986-09-12	1986-09-12	Nordisk Gentofte	Insulinprecursorer
DE3717370A1 (de) *	1987-05-22	1988-12-01	Hoechst Ag	Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
DK336188D0 (da) *	1988-06-20	1988-06-20	Nordisk Gentofte	Propeptider
DE3844211A1 (de) *	1988-12-29	1990-07-05	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung

1989
- 1989-03-20 DK DK134189A patent/DK134189D0/da not_active IP Right Cessation
1990
- 1990-03-15 WO PCT/DK1990/000071 patent/WO1990011299A1/en not_active Ceased
- 1990-03-15 FI FI914419A patent/FI914419A0/fi unknown
- 1990-03-15 AU AU53448/90A patent/AU637365B2/en not_active Ceased
- 1990-03-15 HU HU902706A patent/HUT58349A/hu unknown
- 1990-03-15 JP JP2505142A patent/JPH04503808A/ja active Pending
- 1990-03-15 ES ES90905190T patent/ES2068384T3/es not_active Expired - Lifetime
- 1990-03-15 AT AT90905190T patent/ATE116661T1/de not_active IP Right Cessation
- 1990-03-15 EP EP90905190A patent/EP0463072B1/en not_active Expired - Lifetime
- 1990-03-15 CA CA002049961A patent/CA2049961A1/en not_active Abandoned
- 1990-03-15 DK DK90905190.6T patent/DK0463072T3/da active
- 1990-03-15 KR KR1019910701125A patent/KR920701250A/ko not_active Abandoned
- 1990-03-15 DE DE69015811T patent/DE69015811T2/de not_active Expired - Fee Related
- 1990-03-16 NZ NZ232953A patent/NZ232953A/en unknown
- 1990-03-19 YU YU53290A patent/YU53290A/sh unknown
- 1990-03-19 IL IL93792A patent/IL93792A0/xx unknown
- 1990-03-19 PT PT93502A patent/PT93502B/pt not_active IP Right Cessation
- 1990-03-19 DD DD90338860A patent/DD298788A5/de not_active IP Right Cessation
- 1990-03-19 ZA ZA902086A patent/ZA902086B/xx unknown
- 1990-03-19 US US07/495,798 patent/US5430016A/en not_active Expired - Fee Related
- 1990-03-19 CN CN90101564A patent/CN1045793A/zh active Pending
- 1990-03-20 GR GR900100206A patent/GR1002545B/el unknown
- 1990-03-20 IE IE100490A patent/IE66564B1/en not_active IP Right Cessation
1991
- 1991-09-19 NO NO913687A patent/NO300640B1/no unknown

Also Published As

Publication number	Publication date
NZ232953A (en)	1992-10-28
PT93502A (pt)	1990-11-07
YU53290A (sh)	1992-12-21
DK0463072T3 (da)	1995-06-12
NO913687L (no)	1991-11-19
GR1002545B (el)	1997-01-28
KR920701250A (ko)	1992-08-11
HUT58349A (en)	1992-02-28
JPH04503808A (ja)	1992-07-09
ZA902086B (en)	1990-11-28
CA2049961A1 (en)	1990-09-21
IE901004L (en)	1990-09-20
NO300640B1 (no)	1997-06-30
CN1045793A (zh)	1990-10-03
WO1990011299A1 (en)	1990-10-04
ES2068384T3 (es)	1995-04-16
DE69015811T2 (de)	1995-05-11
FI914419A7 (fi)	1991-09-19
AU637365B2 (en)	1993-05-27
HU902706D0 (en)	1991-12-30
US5430016A (en)	1995-07-04
AU5344890A (en)	1990-10-22
EP0463072B1 (en)	1995-01-04
IL93792A0 (en)	1990-12-23
EP0463072A1 (en)	1992-01-02
DK134189D0 (da)	1989-03-20
ATE116661T1 (de)	1995-01-15
GR900100206A (el)	1991-07-31
NO913687D0 (no)	1991-09-19
DE69015811D1 (de)	1995-02-16
PT93502B (pt)	1996-02-29
IE66564B1 (en)	1996-01-24
FI914419A0 (fi)	1991-09-19

Legal Events

Date	Code	Title	Description
1995-07-06	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69015811T2 (de)	1995-05-11	Insulinverbindungen.
DE3650101T2 (de)	1995-02-23	Analoga von Insulin und deren Herstellungsmethode.
DE68928810T2 (de)	1999-03-18	Analoge vom menschlichen Insulin
DE68912777T2 (de)	1994-05-11	Insulin-analoge.
US4946828A (en)	1990-08-07	Novel insulin peptides
DE68923878T2 (de)	1995-12-21	Rekombinante techniken zur herstellung neuer natriuretischer und gefässerweiternder peptide.
DE19726167B4 (de)	2008-01-24	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE3650055T2 (de)	1994-12-15	Fibroblast-wachstumsfaktor.
EP2041169B1 (de)	2011-08-31	Amidiertes insulin glargin
US5716927A (en)	1998-02-10	Insulin analogs having a modified B-chain
DE3326473A1 (de)	1985-01-31	Pharmazeutisches mittel zur behandlung des diabetes mellitus
DK159856B (da)	1990-12-17	Humaninsulinderivater og farmaceutiske praeparater, som indeholder disse derivater
EP1084248B1 (de)	2006-07-26	Neue insulinanaloga mit erhöhter zinkbindung
DE3883397T2 (de)	1994-02-17	Menschliche insulinanalage und zubereitungen daraus.
MXPA98004945A (en)	1999-06-01	New insulin derivatives with rapid initiation of efe